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Retrospective evaluation of pharmacist screened vancomycin levels and its impact on quality and cost
Jennie T. Mathew, Pharm.D. and Jarrod W. Kile, R.Ph. 
Lehigh VaLLey heaLth Network • aLLeNtowN aNd BethLehem, PeNNsyLVaNia
PurPose 
The objective of this study is to retrospectively evaluate the impact of pharmacist 
interventions on vancomycin serum concentrations. 
BackgrouNd
Literature 
•  To monitor vancomycin efficacy, the 2009 Infectious Disease Society of America/
American Society of Health-System Pharmacists consensus review recommends 
obtaining serum trough concentrations, instead of both peak and trough concentrations. 
–  It is recommended that trough serum concentrations should be obtained just prior 
to the fourth dose.1
Lehigh Valley Health Network (LVHN) 
•  Historically, providers at LVHN utilized physician order entry to order vancomycin 
serum concentrations.
•  Lab orders did not require verification by a pharmacist. 
•  Beginning in February 2010, pharmacists timed orders for vancomycin serum 
concentrations. 
•  The provider may select from the following options: 
– Serum trough concentration prior to the fourth dose.
– Serum trough concentration prior to the next dose.
– Serum random concentration at a time designated by the provider.
•  The intent of the new process was to create standardization throughout the health 
network. 
•  The total costs for vancomycin usage and vancomycin serum concentrations at 
LVHN in 2007 were $194,966 and $392,022, respectively.
 
study desigN
•  A retrospective chart review of patients admitted to LVHN with a minimum of one serum 
vancomycin concentration obtained during the pre- or post intervention periods.
•  The pre- and post intervention periods are defined as December 2009 to January 2010 
and September 2010 to October 2010, respectively.
study PoPuLatioN 
•  Inclusion criteria
– Inpatient adults greater than 18 years old.
–  Patients who had a minimum of one serum vancomycin concentration obtained  
from December 2009 to January 2010.
–  Patients who had a minimum of one serum vancomycin concentration obtained  
from September 2010 to October 2010.
•  Exclusion criteria 
–  Patients admitted to the transitional skilled unit, hospice, or the long term acute  
care facility. 
methods
•  The primary outcome of the study is the number of appropriately ordered serum  
vancomycin concentrations. 
–  Appropriate serum concentrations will be compared pre- and post intervention by 
the type of concentrations requested and the time the concentrations were to be 
obtained. 
–  An appropriate serum concentration, based on type, will be defined as an ordered 
trough or random concentration. All peak serum concentrations will be deemed 
inappropriate.1-5
–  An appropriately timed serum concentration will be defined as a trough concentration 
obtained within one hour of the fourth or next dose. All random concentrations will be 
considered appropriately timed.2-5 
•  The secondary outcome is the number of appropriately obtained 
vancomycin serum concentrations prior to and after pharmacist 
intervention.  
–  A trough serum concentration will be considered appropriately obtained when 
it is acquired between the time it was ordered to be obtained and immediately 
before the next administered dose.
–  A random serum concentration will be considered appropriately obtained 
when it is acquired within one hour before or one hour after the time the 
concentration was to be obtained. 
•  Collected data will be in relation to the first serum vancomycin concentration 
obtained for each patient.
•  Additional data to be collected: 
–  Demographics (age, gender, weight, serum creatinine, estimated creatinine 
clearance).
–  The cost of total vancomycin usage and the cost to obtain all serum 
vancomycin concentrations prior to and after pharmacist intervention.
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